Moon, Suerie2018-07-182018Moon, Suerie. 2018. “Removing the Blindfold on Medicines Pricing.” BMJ (February 26): k840. doi:10.1136/bmj.k840.0959-8138http://nrs.harvard.edu/urn-3:HUL.InstRepos:37263453Tisagenlecleucel (Kymriah), one of several promising chimeric antigen receptor T cell (CAR-T) therapies, is the first gene therapy to get US approval. Novartis announced in September 2017 that the leukaemia treatment would cost $475 000 (£340 000; €390 000)—double the median house price in the US, or 60 years of mortgage payments for the average family.en-USJournal Article2018-07-1420182018-07-1810.1136/bmj.k840